196 related articles for article (PubMed ID: 34313812)
21. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
[TBL] [Abstract][Full Text] [Related]
22. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
[TBL] [Abstract][Full Text] [Related]
23. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Wannarong T; Muangchan C
Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
[TBL] [Abstract][Full Text] [Related]
24. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
van den Hoogen FH; Boerbooms AM; Swaak AJ; Rasker JJ; van Lier HJ; van de Putte LB
Br J Rheumatol; 1996 Apr; 35(4):364-72. PubMed ID: 8624641
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound assessment of skin thickness and stiffness: the correlation with histology and clinical score in systemic sclerosis.
Chen C; Cheng Y; Zhu X; Cai Y; Xue Y; Kong N; Yu Y; Xuan D; Zheng S; Yang X; Zhu Z; Zhao T; Wan W; Zou H; Liang M
Arthritis Res Ther; 2020 Aug; 22(1):197. PubMed ID: 32843083
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
27. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.
Kong X; Sun Y; Dai X; Wang L; Ji Z; Chen H; Jin X; Ma L; Jiang L
Ann Rheum Dis; 2022 Jan; 81(1):117-123. PubMed ID: 34362744
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.
Gheita TA; Sayed S; Azkalany GS; Abaza N; Hammam N; Eissa AH
Clin Rheumatol; 2018 Mar; 37(3):757-763. PubMed ID: 29076114
[TBL] [Abstract][Full Text] [Related]
29. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
[TBL] [Abstract][Full Text] [Related]
30. Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis.
Kersten BE; den Broeder N; van den Hoogen FHJ; Knaapen-Hans HAK; van den Ende CHM; Vonk MC
Rheumatology (Oxford); 2020 Jul; 59(7):1550-1555. PubMed ID: 31628802
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Tanaka Y; Suzuki M; Nakamura H; Toyoizumi S; Zwillich SH;
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1150-8. PubMed ID: 21584942
[TBL] [Abstract][Full Text] [Related]
32. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
33. High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference.
Li H; Furst DE; Jin H; Sun C; Wang X; Yang L; He J; Wang Y; Liu A
Arthritis Res Ther; 2018 Aug; 20(1):181. PubMed ID: 30115105
[TBL] [Abstract][Full Text] [Related]
34. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
35. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
[TBL] [Abstract][Full Text] [Related]
36. Correlations between nailfold microvascular damage and skin involvement in systemic sclerosis patients.
Ruaro B; Pizzorni C; Paolino S; Smith V; Ghio M; Casabella A; Alessandri E; Patané M; Sulli A; Cutolo M
Microvasc Res; 2019 Sep; 125():103874. PubMed ID: 30974112
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database.
Frantz C; Huscher D; Avouac J; Hachulla E; Balbir-Gurman A; Riemekasten G; Siegert E; Lazzaroni MG; Carreira PE; Vettori S; Zanatta E; Ullman S; Czirjàk L; Kowal-Bielecka O; Distler O; Matucci-Cerinic M; Allanore Y;
Autoimmun Rev; 2020 Feb; 19(2):102452. PubMed ID: 31838157
[TBL] [Abstract][Full Text] [Related]
38. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.
Khanna D; Padilla C; Tsoi LC; Nagaraja V; Khanna PP; Tabib T; Kahlenberg JM; Young A; Huang S; Gudjonsson JE; Fox DA; Lafyatis R
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35943798
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
